Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension-Reference-Cited by-同舟云学术

Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension

Published:2019-01-08 Issue:3 Volume:368 Page:462-473
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Trensz Frederic,Bortolamiol Céline,Kramberg Markus,Wanner Daniel,Hadana Hakim,Rey Markus,Strasser Daniel S.,Delahaye Stéphane,Hess Patrick,Vezzali Enrico,Mentzel Ulrich,Ménard Joël,Clozel Martine,Iglarz Marc

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference45 articles.

1. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort;Abbas;Pharmacoepidemiol Drug Saf,2015

2. Deleterious combined effects of salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice;Amiri;J Hypertens,2010

3. Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists

4. Major Role for Hypoxia Inducible Factor-1 and the Endothelin System in Promoting Myocardial Infarction and Hypertension in an Animal Model of Obstructive Sleep Apnea

5. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of novel endothelin antagonists and overview of non-steroidal mineralocorticoid antagonists for treating resistant hypertension: An update;European Journal of Pharmacology;2024-09

2. A New Class of Drugs Approved in the United States for Hypertension: Endothelin Antagonists;The American Journal of Medicine;2024-09

3. Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists;Future Cardiology;2024-07-02

4. March Industry News;Therapeutic Delivery;2024-06-28

5. Aprocitentan: First Approval;Drugs;2024-06-04